IL17A and Hepatitis: Pretreatment of MSCs with IL-17 effectively cured liver injury in a concanavalin A-treated hepatitis mouse model, thus demonstrating that IL-17 ultimately enhanced the MSC-mediated therapeutic effects in an inflammatory environment [39].